Refractory Malignant Solid Neoplasm — Expanded Access Programs
Overview
Right2Hope maintains a directory of 47 expanded access programs, clinical trials, and compassionate use pathways listed for Refractory Malignant Solid Neoplasm. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with refractory malignant solid neoplasm programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 40 programs are currently active or recruiting, with the remaining 7 in other lifecycle stages. Sponsors actively running programs in this area include National Cancer Institute (NCI), Children's Oncology Group, M.D. Anderson Cancer Center, OHSU Knight Cancer Institute, St. Jude Children's Research Hospital.
By recruiting status
Snapshot of where every Refractory Malignant Solid Neoplasm program currently sits in its lifecycle.
- Active / Recruiting40
- Inactive7
Top sponsors
Organisations running the most Refractory Malignant Solid Neoplasm programs in the directory.
- National Cancer Institute (NCI)41 programs
- Children's Oncology Group3 programs
- M.D. Anderson Cancer Center1 program
- OHSU Knight Cancer Institute1 program
- St. Jude Children's Research Hospital1 program
Refractory Malignant Solid Neoplasm programs (47)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Study on Avelumab and M6620 for Treating Advanced Solid Tumors with DNA Repair Issues — M.D. Anderson Cancer Center
- Study on Cabozantinib-S-Malate for Treating Young Patients with Sarcomas, Wilms Tumor, or Other Rare Tumors — National Cancer Institute (NCI)
- Study on Elimusertib for Treating Solid Tumors That Have Returned or Are Resistant to Treatment — National Cancer Institute (NCI)
- Study on Erdafitinib for Treating Children and Young Adults with Advanced Cancers with FGFR Mutations — National Cancer Institute (NCI)
- Study on Ivosidenib for Treating Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders with IDH1 Mutations in Children and Young Adults — National Cancer Institute (NCI)
- Study on Larotrectinib for Treating Children and Young Adults with Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders with NTRK Fusions — National Cancer Institute (NCI)
- Study on Selpercatinib for Treating Advanced Cancers with RET Gene Changes in Children and Young Adults — National Cancer Institute (NCI)
- Study of Onivyde with Talazoparib or Temozolomide in Children with Recurrent Solid Tumors and Ewing Sarcoma — St. Jude Children's Research Hospital
- Study on Genetic Testing-Directed Targeted Therapy for Advanced Solid Tumors, Lymphomas, or Multiple Myeloma — National Cancer Institute (NCI)
- Study on Ado-Trastuzumab Emtansine for Cancers with HER2 Genetic Changes — National Cancer Institute (NCI)
- Study on Afatinib for Cancers with HER2 Genetic Changes (MATCH-Subprotocol B) — National Cancer Institute (NCI)
- Testing Afatinib for Treating Cancers with EGFR Genetic Changes — National Cancer Institute (NCI)
- Study on AZD1775 for Treating Cancers with BRCA Genetic Changes — National Cancer Institute (NCI)
- Study on AZD9291 for Treating Cancers with EGFR Genetic Changes — National Cancer Institute (NCI)
- Study on BVD-523FB (Ulixertinib) for Cancers with Specific Genetic Changes — National Cancer Institute (NCI)
- Study on Copanlisib for Treating Cancers with PIK3CA Mutations — National Cancer Institute (NCI)
- Study on Copanlisib for Treating Cancers with PTEN Gene Changes — National Cancer Institute (NCI)
- Study on Crizotinib for Cancers with ROS1 Genetic Changes (MATCH-Subprotocol G) — National Cancer Institute (NCI)
- Study on Crizotinib for Treating Cancers with MET Exon 14 Deletion Genetic Changes — National Cancer Institute (NCI)
- Study on GDC-0032 (Taselisib) for Treating Cancers with PIK3CA Genetic Changes — National Cancer Institute (NCI)
- Study on Vismodegib for Treating Cancers with Specific Genetic Mutations — National Cancer Institute (NCI)
- Study on GSK2636771 for Treating Cancers with PTEN Genetic Changes — National Cancer Institute (NCI)
- Testing GSK2636771 for Cancers with PTEN Loss of Expression — National Cancer Institute (NCI)
- Study on Ipatasertib for Treating Cancers with AKT Genetic Changes — National Cancer Institute (NCI)
- Study on Erdafitinib for Treating Cancers with FGFR Gene Amplifications — National Cancer Institute (NCI)
- Study on LOXO-101 for Treating Cancers with NTRK Genetic Changes — National Cancer Institute (NCI)
- Study on MLN0128 (TAK-228) for Cancers with mTOR Genetic Changes — National Cancer Institute (NCI)
- Study on MLN0128 (TAK-228) for Cancers with TSC1 or TSC2 Genetic Changes — National Cancer Institute (NCI)
- Study on Olaparib and AZD6738 for Tumors with IDH1 and IDH2 Mutations — National Cancer Institute (NCI)
- Study on Palbociclib as a Targeted Treatment for Cancers with CCND1, 2, or 3 Amplification — National Cancer Institute (NCI)
- Study on Palbociclib for Treating Cancers with CDK4 or CDK6 Gene Changes — National Cancer Institute (NCI)
- Study on Sunitinib for Treating Cancers with cKIT Genetic Changes — National Cancer Institute (NCI)
- Study on Adding DT2216 to Usual Chemotherapy for Relapsed or Hard-to-Treat Solid Tumors and Fibrolamellar Carcinoma — Children's Oncology Group
- Study on Using Nilotinib and Paclitaxel for Patients with Progressive Solid Cancers Previously Treated with Taxane Therapies — National Cancer Institute (NCI)
- Testing Trametinib and Dabrafenib for Cancers with BRAF Genetic Changes — National Cancer Institute (NCI)
- Study on Trametinib for Treating Cancers with BRAF Genetic Changes — National Cancer Institute (NCI)
- Study on Trametinib for Cancers with GNAQ or GNA11 Genetic Changes — National Cancer Institute (NCI)
- Testing Trametinib for Cancers with NF1 Genetic Changes (MATCH-Subprotocol S1) — National Cancer Institute (NCI)
- Study on VS-6063 (Defactinib) for Cancers with NF2 Genetic Changes — National Cancer Institute (NCI)
- Study on Trametinib and Navitoclax for Treating Advanced or Metastatic Solid Tumors — National Cancer Institute (NCI)
- Study on Axatilimab, Retifanlimab, and Paclitaxel for Treating Advanced or Metastatic Solid Tumors — OHSU Knight Cancer Institute
- CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma — Children's Oncology Group
- Study on Ensartinib for Treating Relapsed or Hard-to-Treat Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders with ALK or ROS1 Changes in Children and Young Adults — National Cancer Institute (NCI)
- Study on Genetic Testing-Directed Targeted Therapy for Children with Relapsed or Hard-to-Treat Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders — National Cancer Institute (NCI)
- Tegavivint for Treating Recurrent or Hard-to-Treat Solid Tumors, Including Lymphomas and Desmoid Tumors — Children's Oncology Group
- Testing a New Drug Combination, Entinostat and ZEN003694, for Advanced and Hard-to-Treat Cancers — National Cancer Institute (NCI)
- Study on Tiragolumab and Atezolizumab for Treating Tumors with Missing SMARCB1 or SMARCA4 Genes — National Cancer Institute (NCI)
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Refractory Malignant Solid Neoplasm to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.